1. Lu, Sizhu, Louphrasitthiphol, Pakavarin, Goradia, Nishit, Wilmanns, Matthias, Goding, Colin R. 2021. TBX2 controls a proproliferative gene expression program in melanoma. In Genes & development, 35, 1657-1677. doi:10.1101/gad.348746.121. https://pubmed.ncbi.nlm.nih.gov/34819350/
2. Zhang, Y, Han, Q, Fan, H, Xing, Q, Yan, B. 2013. Genetic analysis of the TBX2 gene promoter in indirect inguinal hernia. In Hernia : the journal of hernias and abdominal wall surgery, 18, 513-7. doi:10.1007/s10029-013-1199-z. https://pubmed.ncbi.nlm.nih.gov/24309999/
3. McIntyre, Alexander J, Angel, Charlotte Z, Smith, James S, Williams, Rich, Mullan, Paul B. . TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers. In Nucleic acids research, 50, 6154-6173. doi:10.1093/nar/gkac494. https://pubmed.ncbi.nlm.nih.gov/35687133/
4. Lu, Juan, Li, Xiang-Ping, Dong, Qi, Kung, Hsiang-Fu, He, Ming-Liang. 2010. TBX2 and TBX3: the special value for anticancer drug targets. In Biochimica et biophysica acta, 1806, 268-74. doi:10.1016/j.bbcan.2010.07.001. https://pubmed.ncbi.nlm.nih.gov/20624445/
5. Zhang, Zeda, Zhou, Chuanli, Li, Xiaoling, Sawyers, Charles L, Mu, Ping. 2020. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. In Cancer cell, 37, 584-598.e11. doi:10.1016/j.ccell.2020.03.001. https://pubmed.ncbi.nlm.nih.gov/32220301/
智鼠故事 
